PTEN and glioblastoma: A total of 55 isocitrate dehydrogenase 1 wild-type glioblastoma patients who received immunotherapy, including 13 long-term responders, were analyzed in one report, and PTEN mutations were identified in 23 out of 32 non-responders, but only in 3 responders (102). PTEN mutations were also associated with an immunosuppressive signature.